Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint...
Celgene International Sarl, a subsidiary of Celgene Corporation , today announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM 1 & 2 phase III studies.
Join the discussion below, or Read more at PR-inside.com.
Since: Sep 12
#1 Jan 7, 2013
As study found that 10 to 30 percent of psoriasis patient develop psoriatic arthritis, but there may some precautions to avoid these as it causes joint pain, joint stiffness and swelling.
#2 Jan 15, 2013
To learn more about Apremilast, check out http://www.rxwiki.com/apremilast
Add your comments below
|Explosion In School Lab Injures 2 Students (Dec '08)||Jul 14||downwithhyde||29|
|Teva Announces Launch of Generic Zoloft (Nov '06)||Jul 13||Liz||1,482|
|State Kicks Kool Smiles in the Teeth (Aug '07)||Jul 12||Tolerman||421|
|Pfizer agrees to note addiction risks in opioid...||Jul 7||BHM5267||2|
|Texas Attorney General sues network marketing c... (Jul '07)||Jun '16||Cynthia Gosney||5|
|Woman is shot on Park Street in Dorchester||Jun '16||bozo||1|
|Chelsea Clinton gives birth to second child, so...||Jun '16||Hostis Publicus||11|
Find what you want!
Search Healthcare Industry Forum Now
Copyright © 2016 Topix LLC